Market research
RPRX Royalty Pharma Plc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 35B
- P/E ratio
- 32.43
- Analyst target
- 65.375
- Dividend yield
- 1.5%
- Beta
- 0.41
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BMVP7Y09
- Market cap
- 35B
- P/E ratio
- 32.43
- Analyst target
- 65.375
- Dividend yield
- 1.5%
- Beta
- 0.41
About
About Royalty Pharma Plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Research context
Royalty Pharma Plc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the RPRX discussion.
5 years, 6 months ago
Royalty Pharma plc is currently in a long term downtrend where the price is trading 5.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.6.
Royalty Pharma plc's total revenue rose by 25.9% to $572M since the same quarter in the previous year.
Its net income has dropped by 88.0% to $171M since the same quarter in the previous year.
Finally, its free cash flow grew by 1146.5% to $566M since the same quarter in the previous year.
Based on the above factors, Royalty Pharma plc gets an overall score of 3/5.